NEW YORK CITY, NY / ACCESS Newswire / November 13, 2026 / Candel Therapeutics (NASDAQ: CADL) shareholders saw as much as roughly 39% of their investment wiped out in after-hours trading on November 12, 2026, after the Company said it now plans to submit its Biologics License Application for aglatimagene in mid-2027. If you lost money on CADL stock, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Candel disclosed the delayed submission timeline alongside its third-quarter results, citing timelines tied to assay refinement and continuing discussions with the FDA. In the months before that announcement, the Company had described manufacturing process validation as progressing well and had said the inputs for the application remained on track for a fourth quarter 2026 submission, while it was also selling stock to the public.

Aglatimagene is Candel's lead prostate cancer drug candidate. On the same evening as the disclosure, the Company entered into a new $50 million stock sale agreement. The investigation concerns what Candel knew about the assay issue, and when, compared with what it told investors.

Investors who bought Candel Therapeutics shares and suffered losses can have their CADL losses reviewed at no cost or reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Billions recovered.

Frequently Asked Questions About the CADL Investigation

Q: What is the CADL securities fraud investigation about?
A: A securities investigation is pending concerning Candel Therapeutics, Inc. (NASDAQ: CADL) regarding potentially materially false or misleading statements. Shares fell approximately 39% after the Company disclosed that it now plans to submit its Biologics License Application for aglatimagene in mid-2027 rather than the fourth quarter of 2026, causing losses for shareholders.

Q: Who is conducting the CADL investigation?
A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased CADL securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered billions of dollars for aggrieved investors.

Q: Who is eligible to participate in the CADL investigation?
A: Investors who purchased CADL stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do CADL investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter?
A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my CADL shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CADL and sold at a loss may still participate in the investigation.

Q: What if my CADL losses are small -- is it still worth contacting a lawyer?
A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP